Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 13561
Country/Region: Côte d'Ivoire
Year: 2016
Main Partner: ACONDA
Main Partner Program: Cote d'Ivoire
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $6,675,479 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $706,243
Care: TB/HIV (HVTB) $433,559
Care: Pediatric Care and Support (PDCS) $180,717
Laboratory Infrastructure (HLAB) $40,000
Testing: HIV Testing and Counseling (HVCT) $220,468
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $378,888
Treatment: Adult Treatment (HTXS) $4,017,860
Treatment: Pediatric Treatment (PDTX) $697,744
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 44
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 158
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 54
GEND_GBV Number of people receiving post-GBV care 2017 212
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 6,453
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 7,024
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 67,804
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 73,441
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 154,722
HTS_TST Service Delivery Point (Facility): Inpatient 2017 74,116
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 1,483
HTS_TST Service Delivery Point (Facility): Outpatient 2017 8,714
HTS_TST Service Delivery Point (Facility): PMTCT 2017 65,900
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 4,509
HTS_TST Sum of Aggregated Age/Sex <15 2017 13,477
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 141,245
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 154,722
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 321
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 372
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 2,761
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 2,991
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 3
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 3
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 28
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 28
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 28
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 3
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 3
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 3
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 9
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 9
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 30
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 2
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 2
PMTCT_ART Already on ART at beginning of current pregnancy 2017 1,092
PMTCT_ART New on ART 2017 1,493
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 66,732
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 1,480
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 738
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 59
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 38
PMTCT_EID Sum of Infant Age disaggregates 2017 2,218
PMTCT_STAT By: Known positives at entry 2017 1,092
PMTCT_STAT By: Number of new positives identified 2017 1,621
PMTCT_STAT Number of new ANC and L&D clients 2017 70,200
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 66,732
PMTCT_STAT Sum of Positives Status disaggregates 2017 2,713
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 536
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 239
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 820
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 779
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 3,629
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 420
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 2,750
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 459
TB_SCREENDX Screen Result: Screened Positive for TB 2017 3,629
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 24,788
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 9,649
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 911
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 931
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 36,279
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 65
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,967
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 27
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,450
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 4,509
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 4,677
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,534
TX_CURR Aggregated Age/Sex: <15 Male 2017 1,596
TX_CURR Aggregated Age/Sex: 15+ Female 2017 24,739
TX_CURR Aggregated Age/Sex: 15+ Male 2017 12,443
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 40,312
TX_CURR Sum of Aggregated Age/Sex <15 2017 3,130
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 37,182
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 40,312
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 1,055
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 1,089
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 12,057
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 6,273
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 20,474
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 20,474
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 43,493
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 34,657
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 1,178
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 1,205
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 20,571
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 10,357
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,544
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 1,599
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 26,846
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 13,504
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 68
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 68
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,544
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,824
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 5,504
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 6,884
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 94
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 92
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4,427
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,271
Cross Cutting Budget Categories and Known Amounts Total: $2,093,558
Human Resources for Health $2,013,558
Food and Nutrition: Policy, Tools, and Service Delivery $15,000
Food and Nutrition: Commodities $15,000
Economic Strengthening $10,000
Education $10,000
Water $10,000
Gender: Gender Based Violence (GBV) $20,000
GBV Prevention
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Implementation
Capacity building
Monitoring and Evaluation